IRIS
LAVATELLI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.332
AS - Asia 2.691
EU - Europa 2.185
SA - Sud America 339
Continente sconosciuto - Info sul continente non disponibili 164
AF - Africa 153
OC - Oceania 6
Totale 9.870
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.188
CN - Cina 1.153
SG - Singapore 659
IE - Irlanda 550
HK - Hong Kong 290
IT - Italia 289
RU - Federazione Russa 275
BR - Brasile 244
DE - Germania 242
FI - Finlandia 239
VN - Vietnam 234
FR - Francia 126
UA - Ucraina 120
GB - Regno Unito 105
ZA - Sudafrica 105
IN - India 88
CA - Canada 66
JP - Giappone 43
SE - Svezia 43
ES - Italia 41
BD - Bangladesh 37
TR - Turchia 33
AR - Argentina 31
PL - Polonia 29
MX - Messico 28
IQ - Iraq 26
NL - Olanda 20
PK - Pakistan 18
MA - Marocco 17
VE - Venezuela 16
CO - Colombia 14
ID - Indonesia 14
AT - Austria 13
BE - Belgio 13
EC - Ecuador 13
LT - Lituania 13
SA - Arabia Saudita 12
IL - Israele 11
AE - Emirati Arabi Uniti 9
CR - Costa Rica 9
CZ - Repubblica Ceca 8
HN - Honduras 8
NI - Nicaragua 8
CL - Cile 7
AL - Albania 6
EE - Estonia 6
KR - Corea 6
PT - Portogallo 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
AU - Australia 5
AZ - Azerbaigian 5
DK - Danimarca 5
EG - Egitto 5
ET - Etiopia 5
GR - Grecia 5
HU - Ungheria 5
JM - Giamaica 5
MY - Malesia 5
PE - Perù 5
SC - Seychelles 5
TH - Thailandia 5
UZ - Uzbekistan 5
CW - ???statistics.table.value.countryCode.CW??? 4
IR - Iran 4
JO - Giordania 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
BO - Bolivia 3
CH - Svizzera 3
DZ - Algeria 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
NP - Nepal 3
RS - Serbia 3
SV - El Salvador 3
TN - Tunisia 3
VG - Isole Vergini Britanniche 3
BG - Bulgaria 2
BH - Bahrain 2
EU - Europa 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
MD - Moldavia 2
MN - Mongolia 2
NG - Nigeria 2
RO - Romania 2
AM - Armenia 1
AW - Aruba 1
BY - Bielorussia 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GH - Ghana 1
GP - Guadalupe 1
GT - Guatemala 1
IS - Islanda 1
Totale 9.693
Salva come PNG Salva come JPEG
Città #
Dublin 550
San Jose 478
Chandler 439
Ashburn 367
Singapore 363
Dallas 314
Hong Kong 285
Beijing 277
Council Bluffs 221
Jacksonville 188
Nanjing 179
Boardman 167
Helsinki 122
Los Angeles 98
Johannesburg 89
Lauterbourg 84
Nanchang 84
Ho Chi Minh City 80
Princeton 80
Lawrence 77
Wilmington 72
Medford 71
New York 70
Santa Clara 64
Hanoi 62
Munich 62
Shenyang 56
Hebei 55
Moscow 46
Jiaxing 44
Changsha 42
Buffalo 41
Shanghai 41
Ann Arbor 38
Hangzhou 38
Milan 37
Pavia 36
Tokyo 34
Tianjin 33
Redondo Beach 32
São Paulo 30
Orem 28
Montreal 25
Turku 23
Frankfurt am Main 21
Norwalk 21
Warsaw 21
Atlanta 18
Piscataway 18
Woodbridge 18
Ankara 17
London 17
Phoenix 17
Boston 16
Chennai 16
Chicago 16
Denver 16
Poplar 15
San Francisco 15
The Dalles 15
Charlotte 14
Rio de Janeiro 14
Brussels 13
Naples 13
Rome 13
Avellino 12
Seattle 12
Stockholm 12
Amsterdam 11
Brooklyn 11
Da Nang 11
Fairfield 11
Manchester 11
Toronto 11
Columbus 10
Falkenstein 10
Haiphong 10
Mexico City 10
Washington 10
Catania 9
Bologna 8
Chandigarh 8
Houston 8
Managua 8
San José 8
Verona 8
Baghdad 7
Caracas 7
Dhaka 7
Newark 7
Belo Horizonte 6
Biên Hòa 6
Bridgeport 6
Campina Grande 6
Cape Town 6
Curitiba 6
Hải Dương 6
Jinan 6
Lahore 6
Las Vegas 6
Totale 6.263
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 242
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 173
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 165
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 147
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 145
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 144
AMICA: an electronic patient record specifically designed for an amyloidosis network 142
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 141
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 135
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 134
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 132
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 131
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 131
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 131
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 131
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 129
Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms 129
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 127
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 123
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 123
A practical approach to the diagnosis of systemic amyloidoses 123
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 122
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 121
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 120
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 120
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 119
Biochemical markers in early diagnosis and management of systemic amyloidoses 119
Prognostication of survival and progression to dialysis in AA amyloidosis 118
A workflow management system for the biological samples exchange within the amyloidosis network 118
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 117
AMICA: an electronic patient record specifically designed for an amyloidosis network. 117
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 115
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 115
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 113
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 113
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 112
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 112
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 111
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 110
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 109
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 109
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 109
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 109
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 109
IceTrack: a biobank information management system maximizing flexibility and usability 107
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis 105
A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils 105
A workflow management system for the biological samples exchange within the amyloidosis network 103
A case of monoclonal gammopathy of renal significance 103
Human wild-type and D76N β2-microglobulin variants are significant proteotoxic and metabolic stressors for transgenic C. elegans 102
Changes in tissue proteome associated with ATTR amyloidosis: Insights into pathogenesis 102
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 100
Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains 100
AA-amyloidosis in cats (Felis catus) housed in shelters 99
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 99
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 99
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. 96
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 95
Regulated expression of amyloidogenic immunoglobulin light chains in mice 95
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 94
Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans 92
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). 92
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 89
Age-related amyloidosis outside the brain: A state-of-the-art review 89
Renal alterations in cats (Felis catus) housed in shelters and affected by systemic AA-amyloidosis: Clinicopathological data, histopathology, and ultrastructural features 88
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity 88
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 88
Dissecting the molecular features of systemic light chain (Al) amyloidosis: Contributions from proteomics 88
Truncation of the constant domain drives amyloid formation by immunoglobulin light chains 87
Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations 85
Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits 84
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 83
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 83
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 83
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 81
Clinical proteomics for diagnosis and typing of systemic amyloidoses 80
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 79
Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. 76
The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis 74
Clinical amyloid typing by proteomics: Performance evaluation and data sharing between two centres 72
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 68
Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations 66
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres 66
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 65
The workings of the amyloid diseases. 65
Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration 64
Systemic amyloidoses and proteomics: The state of the art 62
A practical approach to the diagnosis of systemic amyloidoses 60
Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing 58
Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis 55
Proteomics in protein misfolding diseases. 54
The Protein Network in Subcutaneous Fat Biopsies from Patients with AL Amyloidosis: More Than Diagnosis? 51
Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disorders 51
How do we improve treatments for patients with amyloidosis using proteomics? 50
null 35
Role of extracellular space and matrix remodeling in cardiac amyloidosis 33
Renal amyloid‐A amyloidosis in cats: Characterization of proteinuria and biomarker discovery, and associations with kidney histology 33
null 28
null 6
Totale 9.870
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.841
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.841
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022295 0 0 0 0 6 2 6 39 20 3 38 181
2022/20231.410 181 116 18 82 120 121 10 59 623 8 32 40
2023/2024585 69 112 33 26 47 123 20 42 9 25 42 37
2024/20251.461 45 107 54 39 32 94 66 65 384 56 199 320
2025/20263.787 279 246 383 444 518 174 657 186 374 262 101 163
2026/2027880 77 182 219 387 15 0 0 0 0 0 0 0
Totale 9.870